Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Merck
Baxter
Dow
Express Scripts

Last Updated: June 28, 2022

Validus Pharms Company Profile


✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for VALIDUS PHARMS, and what generic alternatives to VALIDUS PHARMS drugs are available?

VALIDUS PHARMS has twenty-one approved drugs.

There is one US patent protecting VALIDUS PHARMS drugs.

There is one patent family member on VALIDUS PHARMS drugs in one country and ten supplementary protection certificates in six countries.

Summary for Validus Pharms
International Patents:1
US Patents:1
Tradenames:19
Ingredients:17
NDAs:21

Drugs and US Patents for Validus Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Validus Pharms LASIX furosemide TABLET;ORAL 016273-002 Approved Prior to Jan 1, 1982 AB RX Yes No See Plans and Pricing See Plans and Pricing
Validus Pharms DEMEROL meperidine hydrochloride INJECTABLE;INJECTION 005010-003 Approved Prior to Jan 1, 1982 DISCN No No See Plans and Pricing See Plans and Pricing
Validus Pharms LOTENSIN benazepril hydrochloride TABLET;ORAL 019851-002 Jun 25, 1991 AB RX Yes No See Plans and Pricing See Plans and Pricing
Validus Pharms DEMEROL meperidine hydrochloride SYRUP;ORAL 005010-005 Approved Prior to Jan 1, 1982 DISCN No No See Plans and Pricing See Plans and Pricing
Validus Pharms LOPRESSOR metoprolol tartrate TABLET;ORAL 017963-002 Approved Prior to Jan 1, 1982 AB RX Yes No See Plans and Pricing See Plans and Pricing
Validus Pharms CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER cefotaxime sodium INJECTABLE;INJECTION 050596-003 May 20, 1985 DISCN No No See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Validus Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Validus Pharms ROCALTROL calcitriol CAPSULE;ORAL 018044-002 Approved Prior to Jan 1, 1982 4,225,596 See Plans and Pricing
Validus Pharms NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-003 Approved Prior to Jan 1, 1982 3,454,698 See Plans and Pricing
Validus Pharms ROCALTROL calcitriol CAPSULE;ORAL 018044-002 Approved Prior to Jan 1, 1982 4,341,774 See Plans and Pricing
Validus Pharms NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-001 Approved Prior to Jan 1, 1982 3,454,554 See Plans and Pricing
Validus Pharms NORPRAMIN desipramine hydrochloride TABLET;ORAL 014399-004 Approved Prior to Jan 1, 1982 3,454,554 See Plans and Pricing
Validus Pharms TRENTAL pentoxifylline TABLET, EXTENDED RELEASE;ORAL 018631-001 Aug 30, 1984 4,189,469 See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for VALIDUS PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Capsules 200 mg and 300 mg ➤ Subscribe 2007-08-21
➤ Subscribe Extended-release Capsules 100 mg ➤ Subscribe 2014-05-23

Supplementary Protection Certificates for Validus Pharms Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0454511 99C0009 Belgium See Plans and Pricing PRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
0443983 C00443983/03 Switzerland See Plans and Pricing PRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009
0502314 SPC/GB02/037 United Kingdom See Plans and Pricing PRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419
0266730 C970043 Netherlands See Plans and Pricing PRODUCT NAME: DOLASETRON, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZUURADDITIEZOUT, IN HET BIJZONDER HET MESYLAAT; NAT REGISTRATION NO/DATE: RVG 21707 - RVG 21709 19970623; FIRST REGISTRATION: GB PL 04425/0150, PL 04425/0152, PL 04425/0154 19960926
0454511 SPC/GB99/008 United Kingdom See Plans and Pricing PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015
0565634 06C0030 France See Plans and Pricing PRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Harvard Business School
Mallinckrodt
Baxter
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.